Biogen (Nasdaq: BIIB) is preparing to present research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, the largest study to capture the widespread impact of the disease.
The US biotech major will also provide an update on clinical findings from the company’s broad portfolio of MS therapies at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London next week.
The Biogen-sponsored MS Cost of Illness (COI) study further builds on the highly influential and frequently cited 2005 European COI study, which examined the burden of MS on patients and their caregivers in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze